Reshma has dedicated her career to improving the lives of patients, including the last 15+ years through the development of new medicines. She joined Vertex in 2017 and, in collaboration with the executive committee, board of directors and everyone at Vertex, she leads and executes the company's strategy and ambitious mission of transforming the lives of people with serious diseases. Prior to taking on her role as CEO and President, she was the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs.
She earned her medical degree, with honors, from the seven-year medicine program at the Boston University School of Medicine and completed the General Management Program at Harvard Business School. She completed her internship and residency in internal medicine at the Massachusetts General Hospital (MGH) and her fellowship in nephrology through the MGH and Brigham and Women's Hospital combined program.
Reshma is passionate about developing and supporting the next generation of scientists and giving back to her community - serving as a member of the board of directors of the Biomedical Science Careers Program, an organization dedicated to supporting underrepresented students to pursue a career in STEM. She's also a member of the Boston University School of Medicine Dean's Advisory Board, the MGH Board of Trustees, and the Ginkgo Bioworks board of directors. She is a Fellow of the American Society of Nephrology and was on the inaugural board of directors of the Kidney Health Initiative.
She is the recipient of the Harvard Medical School Excellence in Teaching Award. In 2019, Reshma received the TiE Boston Healthcare Leadership Award and was named one of Boston Business Journal's Power 50. In 2020, Business Insider named her one of 10 people transforming health care, and she was included on the PharmaVOICE 100 list of the most inspiring and influential leaders in the life sciences and Boston Business Journal's list of Women Who Mean Business. In 2021, Dr. Kewalramani received the Golden Door Award from the International Institute of New England and was named a New Englander of the Year by the New England Council. Under her leadership as CEO, Vertex was ranked #2 on The Commonwealth Institute's Top Women-Led Businesses in Massachusetts in 2021.
FIRM PROFILE
We strike at the core of serious diseases to change people's lives. Bringing together the brightest minds, investing in science and taking smart risks, we go all in. For the lives we have changed and for those who are still waiting, we will never stop fighting until we discover cures.
We have research and development sites and commercial offices around the world, all dedicated to bringing the next transformative treatments to people with serious diseases. Our headquarters are in Boston and London.
We're focused on discovering, developing and bringing innovative medicines to people with serious diseases so they can lead better lives. In pursuit of this mission, we are advancing a robust research pipeline that includes potentially transformative treatments for cystic fibrosis, pain, sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, Duchenne muscular dystrophy, type 1 diabetes and more.
